Gilead Sciences reported its second quarter 2025 financial results, posting revenue of $7.08 billion, surpassing the estimated $6.97 billion. Adjusted earnings per share (EPS) came in at $2.01, slightly above the $1.98 estimate. Product sales were projected between $28.30 billion and $28.70 billion, close to the $28.45 billion consensus. Key product performances included Biktarvy with $3.53 billion in revenue, exceeding the $3.37 billion estimate, and Trodelvy generating $364 million, above the $345.4 million forecast. However, Veklury revenue was $121 million, below the estimated $200.1 million. Gilead's total revenue increased 2% year-over-year, driven by higher sales of HIV treatments, Livdelzi (seladelpar), and Trodelvy, partially offset by declines in chronic hepatitis C virus products. The company also secured FDA approval for Yeztugo, the first twice-yearly HIV pre-exposure prophylaxis (PrEP). Net income for the quarter was $1.96 billion. Additionally, several other biotech companies, including RAPT Therapeutics, Celldex Therapeutics, Arcellx, Janux Therapeutics, Nektar Therapeutics, Cidara Therapeutics, and 10x Genomics, reported their second quarter 2025 financial results and corporate updates during the same period.